News

Bristol-Myers Squibb and Otsuka Pharma said that the study results were consistent with 12-month data in which Sprycel demonstrated higher and faster rates of complete cytogenetic response (CCyR)and

McKesson claims the CytoCare is the only proven automation solution for compounding hazardous IVs used for chemotherapy and monoclonal antibody therapy. The new technology will enable the 800-bed

Sangart has entered into this CRADA with the US Naval Medical Research Center and the Uniformed Services University of Health Sciences. The agreement will allow the US Navy

As per the agreement, Ascenta will conduct its first Phase I trial of AT-406 in adults with AML in combination with the standard AML induction regimen, and expects

Both compounds were discovered and developed by Gruenenthal and represent novel molecules with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005

Most recently, Nagel worked as the head of General Electric Company (GE) Oil & Gas Global Services and was based in Florence, Italy. Nagel held senior leadership positions

unithink said that Cline comes to the company after successful stints at National Clinical Research and etrials, where he was a founder and CEO. While at etrials, Cline

Marck Biosciences intends to increase its manufacturing capacity for large volume injectibles by over 33% by March 2011, The Business Standard reported. The company plans to manufacture large

Under the collaboration agreement, Invida will be Sinclair’s exclusive partner in eleven markets within the Asia Pacific region for its dermatology and wound care brands in what is